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Both healthy and cancerous breast tissue is heterogeneous, which is a bottleneck for proteomics-
based biomarker analysis, as it obscures the cellular origin of a measured protein. We therefore
aimed at obtaining a protein-level interpretation of malignant transformation through global
proteome analysis of a variety of laser capture microdissected cells originating from benign
and malignant breast tissues. We compared proteomic differences between these tissues, both
from cells of epithelial origin and the stromal environment, and performed string analysis. Dif-
ferences in protein abundances corresponded with several hallmarks of cancer, including loss
of cell adhesion, transformation to a migratory phenotype, and enhanced energy metabolism.
Furthermore, despite enriching for (tumor) epithelial cells, many changes to the extracellular
matrix were detected in microdissected cells of epithelial origin. The stromal compartment
was heterogeneous and richer in the number of fibroblast and immune cells in malignant sec-
tions, compared to benign tissue sections. Furthermore, stroma could be clearly divided into
reactive and nonreactive based on extracellular matrix disassembly proteins. We conclude that
proteomics analysis of both microdissected epithelium and stroma gives an additional layer of
information and more detailed insight into malignant transformation.
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Significance of the study
In this work, we describe intra- and extracellular proteomic
changes in microdissected breast tissue sections with vary-
ing stages of disease, in a variety of cell types. Stroma in
(malignant) breast tissue is heterogeneous, as evidenced by
a clear distinction of two clusters of reactive and nonreac-
tive stroma. This difference could be mainly attributed to
extracellular matrix disassembly proteins. Even though ex-
tracellular proteomic changes were readily captured in mi-
crodissected epithelium, proteomic analysis of stroma pro-
vided more detailed analysis of malignant transformation.
Thus, our study emphasizes the power of proteomics work-
flows thatmake use of laser capturemicrodissection samples
from different cellular origin.
1 Introduction
Breast cancer is a heterogeneous disease, which can be classi-
fied into a variety of different subtypes based on genetic and
histopathological features [1, 2]. Different subtypes are asso-
ciated with different prognosis and outcome, and therefore
detailed molecular characterization is important to obtain a
better understanding of the disease, and to identify novel pu-
tative targets for therapy [3]. Although molecular subtypes
were first described by gene expression profiling, advance-
ment in proteomics technology now also enables molecular
subtyping of breast cancer at the protein level [4]. However,
identifying novel putative markers is still a challenging task,
since tumor tissue is not only genetically heterogeneous, but
also histologically. Breast tumor tissue consists of malignant
tumor epithelium, and varying amounts of connective tissue
and other cell types, including leukocytes, endothelial cells,
fibroblasts, and normal epithelium. All these compartments
contribute in concert to the development of the tumor. To
molecularly characterize a tumor, detailed information of the
total make-up of the tumor is ideally obtained in a spatially
resolved or cell type specific manner. Instead, when whole
tissues or sections are used for protein profiling, a combined
protein quantity of each region of tissue is obtained, which
may complicate accurate characterization of the tumor, for
example when proteins are present in distinct regions and
have different functions. Additionally, in comparative analy-
sis, for example, between tumors with different clinical out-
come, variability in relative amounts of tumor epithelial cells
and other cell types will add noise, and prevent detection of
more subtle changes in protein expression. Strict inclusion
criteria, for example, selection based on the number of tumor
nuclei or tumor area, can alleviate possible confounding due
to intratissue heterogeneity [5]. However, this will limit the
number of tissues that can be included in the analysis, and
may also introduce bias into the analysis, for example, toward
higher-grade tumors.
Stromal interference can be minimized by enriching tu-
mor epithelial cells with laser capturemicrodissection (LCM).
We have previously successfully implemented an LCM-based
proteomic workflow to develop both prognostic and predic-
tive proteomic signatures in breast cancer based on epithelial
tumor cells [6, 7]. LCM-based proteomics has also previously
been used to characterize specific regions of interest, in both
healthy and malignant tissues, such as blood vesicles [8] and
amyloid plagues [9]. Microdissected tissue characterization
does not need to be limited to a single cell type, and various
regions of tissues can be separately microdissected and ana-
lyzed, which allows for region-specific proteomic maps to be
obtained. Such region- and cell-type-specific proteomic maps
could potentially give more depth to the characterization of
disease stages, subtypes, and the identification of putative
protein biomarkers.
As a proof of principle, we performedMS-based proteomic
analyses on microdissected normal, benign, premalignant,
and malignant epithelium, as well as stroma and infiltrate
from fresh-frozen breast tissues with varying stages of dis-
ease. We characterized differences between normal and ma-
lignant epithelium and stroma, thereby showing the addi-
tional value of a cell-type-specific LCM-proteomics workflow.
2 Materials and methods
2.1 Patients and tumor tissue
Snap frozen breast tumor tissues (n = 38) were used from
our liquid N2 bio bank, which were selected based on inva-
sive tumor cell percentage (nucleus count). This study was
approved by the Medical Ethics Committee of the Erasmus
MC Rotterdam, the Netherlands (MEC 02.953), and was per-
formed in accordance to the Code of Conduct of the Fed-
eration of Medical Scientific Societies in the Netherlands
(http://www.federa.org/). An overview of histological and
molecular characteristics of selected tumors is provided in
Supporting Information Table 1.
2.2 Cryosectioning and laser capture
microdissection
Cryosectioning and LCM were performed as described previ-
ously [10]. Briefly, 8 m tissue sections were cut and melted
on an ultraviolet (UV)-treated polyethylene naphthalate slide
(Carl ZeissMicroImaging,Munich, Germany). Sectionswere
fixed in ice-cold 70% v/v ethanol/Milli-Q water, dehydrated
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in 100% ethanol and stored at –80C. Prior to LCM, sections
were rehydrated in tap water, stained with hematoxylin, and
dehydrated in increasing concentrations of ethanol inMilli-Q
water. LCM was performed using a type P-MB device (Carl
Zeiss MicroImaging) and completed within 1.5 h after stain-
ing. From each slide, an area of 500 000 m2 was collected
in opaque adhesive caps (Carl Zeiss MicroImaging), equiva-
lent to4000 epithelial cells (assuming 10 m3 per cell [11]).
Collected cells were dissolved in 20 L of 0.1% w/v RapiGest
in 50 mM ammonium bicarbonate and stored at –80C until
further processing.
2.3 Protein digestion
Cells were lysed by sonication in a cup horn sonicating (wa-
ter) bath, using an Ultrasonic Disruptor Sonifier II (Model
W-250/W-450, Bransons Utrasonics, Danbury, CT, USA) for
1 min at 70% amplitude. Proteins were denatured at 99C for
5 min, reduced by incubating with 5 mM DTT at 60C for
30 min, and alkylated with 15 mM IAM in the dark at room
temperature for 30 min. Subsequently, 1 g trypsin was
added (approximately 1:50 ratio protease:protein) and sam-
ples were incubated at 37C for 4 h. After digestion, RapiGest
SF was degraded by acidifying to 0.5% v/v TFA and incubat-
ing for 30 min at 37C.
2.4 LC-MS
Measurements were performed with a nano-LC system (Ul-
timate 3000, Dionex, Amsterdam, The Netherlands) coupled
online to a hybrid linear ion trap/Orbitrapmass spectrometer
(LTQ-Orbitrap-XL, Thermo Fisher Scientific, San Jose, CA,
USA) as previously reported [12]. Samples were desalted on a
trap column (PepMap C18, 300 m id × 5 mm length, 5 m
particle size (d.p.), 100 A˚ pore size; Thermo Fisher Scientific)
and then separated on the analytical column (PepMap C18,
75 m i.d. × 500 mm, 3 m d.p. and 100 A˚ pore size), with
the following binary gradient: 0 to 25% solvent B in 120 min
and 25 to 50% solvent B in a further 60 min, at a flow rate of
250 nL/min. Solvent A consisted of 2%ACN and 0.1% formic
acid inHPLCwater, and solvent B consisted of 80%ACN and
0.08% formic acid in HPLC water. For MS detection, a data-
dependent acquisition method was used. A high-resolution
survey scan from 400 to 1800 Th. was detected in the Orbitrap
(target of automatic gain control = 106, maximum injection
time= 1000ms, resolution= 30 000 at 400 Th). Based on this
full scan, the five most intensive ions were consecutively iso-
lated (target of automatic gain control = 104 ions, maximum
injection time = 400 ms), fragmented by collision induced
dissociation (35% normalized collision energy), and detected
in the ion trap. Selected precursor masses ±5 ppm were
excluded for MS/MS fragmentation for 3 min or until the
precursor intensity fell below an S/N of 1.5 for more than ten
scans. The MS proteomics data have been deposited to the
ProteomeXchange Consortium [13] via the PRIDE partner
repository with the dataset identifier PXD003632.
2.5 Data analysis
Label-free quantification was performed in MaxQuant [14]
(v. 1.4.1.2). Data were searched using the Andromeda [15]
search engine against a concatenated target-decoy database
(UniProt-Swiss-Prot 2014-4Homo sapiens canonical reference
proteome). The cleavage rule was set to trypsin (no P-rule),
and an initial precursor mass window of 20 ppm and frag-
ment mass tolerance of 0.5 Da was used. Oxidation of me-
thionine and protein N-terminal acetylation were set as vari-
able modifications, and carbamidomethylation of cysteine as
a fixed modification. Peptide and protein identifications were
filtered to 1% FDR based on decoy counting. Alignment of
peptides, for which fragmentation data were not obtained
in each individual run, was enabled through the “match be-
tween run” option and the minimum number of peptides
per protein required for quantitation was set to 2 (label-free
quantification minimum ratio count).
Protein annotation, PCA, and testing for differences
(two-sided Welch test) were performed in Perseus [16]. Pro-
tein abundances were log transformed and replicates were
averaged prior to testing. Annotation enrichment analysis
was performed in Perseus or DAVID [17]. A STRING [18]
protein interaction network selected stromal proteins was
created in Cytoscape 3.4.0 [19] via Stringapp (http://www.
cgl.ucsf.edu/cytoscape/stringApp/index.shtml). Aminimum
interaction score of 0.4 was applied. Hierarchical cluster
analysis was performed in the programCluster [20] using cor-
relation as a distance metric and centroid linkage as agglom-
erationmethod. Resulting data were visualized in JAVA Tree-
view [21]. Venn diagrams were plotted in the Venn diagram
tool (http://bioinformatics.psb.ugent.be/webtools/Venn/).
All other graphs were prepared in Microsoft Excel or
GraphPad Prism 5.
3 Results
3.1 Protein identifications in microdissected regions
We microdissected a variety of cell types (n = 61) from
breast tissues (n = 38) for downstream global proteomic
analysis (Fig. 1). Microdissected tissues included histologi-
cally normal epithelium and stroma from benign and malig-
nant lesions (grouped as benign epithelium/stroma), benign
epithelium and stroma from fibroadenomas, premalignant
epithelial cells from ductal carcinoma in situ, and invasive
tumor epithelium, stroma, and infiltrating leukocytes from
breast cancer tissues (Fig. 1, Table 1, Supporting Informa-
tion Table 1, representativeHE staining shown in Supporting
Information Fig. 1).
In the complete tumor set (n = 38), 2995 protein groups
were identified (excluding common contaminants), of which
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Figure 1. Schematic represen-
tation of the LCM-proteomics
workflow. Fresh frozen breast
tissues were subjected to LCM,
from which both epithelial and
stromal cell regions were col-
lected. Proteins were extracted,
trypsin digested, and subjected
to nano-LC-MS/MS analysis, af-
terwhich the protein abundance
data were analyzed by PCA.
Table 1. Number of patients and microdissected areas from tis-
sue cryosections
Patient lesion n
patients
Microdissected
area
n
microdissected
Benign 2 Benign
epithelium
2
Stroma 2
Fibroadenoma 2 Benign
epithelium
2
Stroma 1
CIS 3 Benign
epithelium
2
Carcinoma
In-Situ
1
Stroma 2
Malignant 31 Benign
epithelium
4
Carcinoma
In-Situ
3
Malignant
epithelium
26
Infiltrate 3
Stroma 13
Total 38 61
719 were detected with fragmentation based evidence in all
dissected areas (Supporting Information Fig. 2). Malignant
tumors typically harbored larger groups of invasive cells that
could be microdissected from their environment with rela-
tively high purity, as assessed by histologically reviewing pic-
tures taken from all microdissected areas. In samples from
which microdissected tumor cells were collected (n = 26),
2663 protein groups were identified with at least one sup-
portive MS/MS spectrum, of which 357 exclusively in the tu-
mor group. Among these proteins was the epidermal growth
factor receptor, a tumor marker that promotes tumor growth
and survival, which is often overexpressed in tumors that do
not express ER, progesterone receptor (PR), or human epi-
dermal growth factor receptor (HER2) [22], clinically used
markers on which therapy is based. We detected epidermal
growth factor receptor with MS/MS fragmentation data in a
microdissected triple negative tumor section, with 29 unique
peptides, corresponding to 33% sequence coverage and an
estimated abundance that was among the top ten most abun-
dant proteins detected in malignant cells. In the group of
microdissected ductal carcinoma in situ cells (n = 4), 1927
protein groups were detected, of which 1865 protein groups
overlapped with malignant cells and 43 were unique to this
group (Supporting Information Fig. 2 and Supporting Infor-
mation Table 2).
Histologically normal cells that formmammary glands are
smaller than tumor cells, and consist of two layers of epithe-
lial cells. These cells were therefore more difficult to collect
with high purity due to their smaller size. Despite the lower
purity and relatively small sample of tissues from which be-
nign epithelial cells were collected, 1850 protein groups were
identified with MS/MS evidence, of which 43 were unique
(Supporting Information Fig. 2 and Supporting Information
Table 2). Among the proteins that were only detected with
MS/MS evidence in microdissected histologically normal
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Figure 2. Dynamic range and
abundance of selected proteins
inmicrodissected areas. (A) Pro-
teins from each microdissected
region were sorted on me-
dian abundance. Selected tu-
mor (HER2, ER, and PR) markers
are highlighted. (B) Abundance
of the stromal marker tenascin
and epithelial marker -catenin,
in malignant and histologically
normal sections.
cells were several basement membrane proteins that are
moderately expressed in breast tissues, such as nestin and
tensin-1.
Stroma, the connective tissue of the breast, is heteroge-
neous and consists of varying amounts of different cells, such
as fibroblasts, endothelial cells, adipocytes, leukocytes and,
in malignant tissue, tumor cells. We identified 1131 protein
groups in malignant stroma and 418 protein groups in be-
nign stroma, of which 83 stromal proteins were not detected
in other microdissected cell types. This included proteins
as CD163, a marker for macrophages, and Von Willebrand-
factor, a marker for endothelial damage/dysfunction. Lastly,
leukocytes were microdissected from malignant tissues that
had high numbers of infiltrating cells. In the microdis-
sected areas enriched with leukocytes, 1486 protein groups
were identified, of which 82 were not identified in other
microdissected regions (Supporting Information Fig. 2).
3.2 Dynamic range and detection of (clinically
relevant) breast cancer markers
The dynamic range of peptide abundances at the peptide-
spectrum match level was approximately three to four orders
of magnitude, which translated into an estimated protein dy-
namic range of six to seven orders of magnitude (Fig. 2A and
Supporting Information Fig. 3). Intensity distributions var-
ied between microdissected regions, as a result of a varying
number of proteins with large differences in abundances. To
verify data normalization, we selected two proteins, the ep-
ithelial marker -catenin and the stromal marker tenascin-1
that covered most of the abundance range, and for which dif-
ferences in expression betweennormal andmalignant tissues
are well described [23]. While both markers were detected in
all microdissected areas, abundance of -catenin was lower
in malignant epithelium (p< 0.01) but not in stroma (p = 1),
whereas tenascin had a higher abundance in malignant
stroma (p = 0.03) but not epithelium (p = 0.7, Fig. 2B). Ad-
ditionally, we compared levels of the ER, PR, and HER2.
All of these markers were detected in the lower end of the
abundance range in malignant epithelium in ER and HER2
positive tumors (Fig. 2A). Neither ER nor PR was detected in
ER-negative tumors.HER2 is amplified in approximately 20%
of breast cancer cases, which leads to elevated transcript and
protein levels. Median abundance of HER2 was among the
lowest-abundant proteins. However, samples with an HER2
amplification had HER2 protein levels that were over three
orders of magnitude higher (Fig. 2A).
3.3 Protein expression and function in
microdissected regions of interest
We performed a PCA on protein abundances to classify mi-
crodissected regions of interest based on the largest differ-
ences between samples (Fig. 3). Principal components 1 and
3 most accurately clustered samples according to dissected
areas and cellular types. The largest variance was observed in
stroma, where two apparent clusters were formed, one homo-
geneous, more tightly clustered group consisting mainly of
stroma dissected from histologically normal tissue sections
(“stroma” cluster). A second heterogeneous stromal cluster
explained over 50% of the variance in the dataset that con-
sisted mainly of malignant stroma, as well as stroma dis-
sected fromafibroadenoma (“reactive stroma” cluster, Fig. 3).
Proteins with the highest loadings in principal component 1
were enriched for intracellular (GO cellular compartment:
intracellular part, p < 0.01) and extracellular proteins (GO
cellular compartment: extracellular region, p< 0.01) for neg-
ative and positive loadings, respectively (Figs. 3 and 4). In
principal component 3, proteins with the highest loadings
were enriched for immune regulatory proteins (GO biolog-
ical process: immune system process, p < 0.01). Principal
component 3 progressively separated epithelial cells of in-
creasing malignancy, with the lowest scores for histologically
normal epithelium, followed by epithelium from fibroade-
nomas, ductal carcinoma in situ and invasive carcinoma.
Similarly, samples in stromal cluster 2, which had higher
scores in principal component 3, were mainly of invasive
origin.
ThePCA showed that eachmicrodissected cell type or com-
partment could nearly completely be distinguished based on
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Figure 3. PCA scores plot of princi-
pal components 1 and 3. Microdis-
sected samples clustered according to
their histology, with principal compo-
nent 1 discriminating between stroma
and epithelium and principal compo-
nent 3 discriminating between malig-
nancy, on the basis of expression of
immune regulatory proteins. Red filled
squares: microdissected infiltrate from
malignant tumor sections; black filled
circles: microdissected malignant tu-
mor epithelium; orange filled circles:
microdissected ductal carcinoma in
situ epithelium; blue filled circles: mi-
crodissected epithelial cells from fi-
broadenoma sections; green filled cir-
cles: microdissected epithelial cells
from histologically normal sections.
Black circles: stroma dissected from
histologically malignant sections; blue
circles: stroma dissected from a fi-
broadenoma section; orange circles:
stroma dissected next to ductal car-
cinoma in situ lesions; green circles:
stroma dissected from histologically
normal sections.
expression of extracellular and immune regulatory proteins.
To characterize these differences in more detail, we next per-
formed a cluster analysis on the data and annotated the most
abundant protein clusters (Fig. 4 andSupporting Information
Table 3). Corresponding to the PCA, stromal samples clus-
tered separately from epithelial cells and leukocytes, and the
majority of normal and benign microdissected stromal sam-
ples formed a homogeneous cluster. Stromal samples from
histologicallymalignant sections, alongwith stromadissected
from a fibroadenoma, were separated from this cluster and
had a higher abundance of extracellular matrix (ECM), cell
adhesion, and cytoskeletal proteins (Fig. 4, protein clusters 1,
2, and 5). Histologically normal epithelium and epithelium
dissected from fibroadenomas were also separated from each
other based on these protein clusters, where epithelium from
fibroadenomas had a lower expression of the extracellular
region andmatrix proteins (protein cluster 1).Malignant cells
were characterized with loss of cell adhesion and cytoskeletal
organizing proteins and higher expression of mitochondrial
proteins (protein clusters 2, 5, and 6). The clinically relevant
markers ER, PR, and HER2 were detected in clusters 4 and 7.
Individual protein abundances of ER, PR, and HER2 did not
fully agree with immunohistochemical assessment of the tu-
mor, with notable discrepancies found for ER in tumors that
were immunohistochemically scored with negative PR ex-
pression, a marker for an active ER (Supporting Informa-
tion Fig. 4). In tumors that were immunohistochemically ER
positive, the majority of samples had detectable ER expres-
sion (0/6 ER negative vs. 16/21 ER positive, Fisher’s exact
p = 0.07).
3.4 Differences in protein expression between
benign and malignant regions of interest
Proteins that were differentially abundant between malig-
nant and normal epithelium could be associated with several
hallmarks of cancer (Table 2, Supporting Information Tables
4 and 5). The GOs “ECM” (18% of differentially abun-
dant proteins) and “basement membrane” (9%) together
accounted for the majority of proteins that had a lower
abundance in malignant epithelium. Additionally, proteins
involved in cell adhesion (22% of differentially abundant
proteins), response to wounding (12%), and cytoskeletal
organization (11%) had a lower abundance. Among these
proteins were ECMproteins, such as laminin B2 (fold-change
= –9.5, p < 0.01), serpin C1 (fold-change = –7.4, p < 0.01),
and collagen VII type A1 (fold-change = –10.5, p< 0.01), but
also intracellular proteins such as annexin A1 (fold-change
= –4.0, p< 0.01) and calponin (fold-change = –8.6, p< 0.01;
Supporting Information Table 4).
Proteins that had a higher abundance in malignant
epithelium were enriched in transmembrane proteins (41%,
p < 0.01), proteins located in the Golgi apparatus (19.2%,
p < 0.01), and mitochondrial proteins (23%, p = 0.028).
Among proteins with largest fold-changes were pro-
migratory ECM proteins including fibronectin (fold-
change = 1.9, p < 0.01) and versican (fold-change = 2.7,
p< 0.01), intracellular proteins such as the ribonucleoprotein
major vault protein (fold-change = 2.8, p < 0.01) and the
cytokine-induced protein signal transducer and activator of
transcription 1 (fold-change = 2.3, p < 0.01); along with
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Figure 4. Heatmap of a cluster analysis based on protein abundances in each microdissected sample. Full cluster analysis and zoomed
selected clusters that were strongly enriched in indicated cellular location or biological processes, as well as clusters around the markers
ER, PR, and HER2.
proteinswith unknown function such as pyridoxal-dependent
decarboxylase domain containing 1 (fold-change = 3.8, p <
0.01; Supporting Information Table 4).
Protein abundances in microdissected stroma were more
heterogeneous, most likely as a result of varying number of
stromal cells in histologically malignant sections, compared
to stroma from histologically normal tissue. Among extra-
cellular proteins with largest difference in abundance were
tenascin-1 (fold-change = 5.0, p = 0.03), fibronectin (fold-
change = 3.8, p< 0.01), and anterior gradient protein 2 (fold-
change = 3.7, p < 0.01; Supporting Information Table 4).
Only a few markers had a significantly lower expression in
malignant stroma, which included heparin cofactor 2 (fold-
change = –1.2, p = 0.01), hemopexin (fold-change = –1.2, p
= 0.02), and decorin (fold-change = –0.9, p = 0.04). Approx-
imately 25% of differentially abundant extracellular proteins
between normal and malignant regions were concordant
in both cells of epithelial origin and stroma. Discrepancies
were mainly found for intracellular proteins, such as the cy-
toskeletal organizing proteins filamin-A (fold-change = –3.7,
p < 0.01) in epithelium versus 2.0, p < 0.01) in stroma) and
caldesmon (fold-change= –4.0, p< 0.01 in epithelium versus
Table 2. Enriched GO terms in differentially abundant proteins between benign and malignant cells of epithelial origin
Term Description Count (%) Fold enrichment Benjamini–Hochberg adjusted p-value Direction
GO:0031012 ECM 44 (18%) 5.0 3.3 × 10–19 Down in malignant
GO:0007155 Cell adhesion 53 (22%) 3.9 3.4 × 10–16 Down in malignant
GO:0005604 Basement membrane 22 (9%) 7.3 6.8 × 10–13 Down in malignant
GO:0009611 Response to wounding 29 (12%) 2.7 7.6 × 10–04 Down in malignant
GO:0007010 Cytoskeleton organization 28 (11%) 2.7 8.3 × 10–04 Down in malignant
GO:0031224 Intrinsic to membrane 79 (41%) 1.8 1.7 × 10–07 Up in malignant
GO:0005794 Golgi apparatus 37 (19%) 2.5 1.5 × 10–05 Up in malignant
GO:0005739 Mitochondrion 45 (23%) 1.6 0.03 Up in malignant
C© 2017 Proteomics Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. www.proteomics-journal.com
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Figure 5. Protein abundance
and immunostaining of cal-
desmon. (A) Protein abundance
in benign and malignant ep-
ithelium and stroma. (B.I) Cy-
toplasm and membrane stain-
ing in; (a) myoepithelial layer of
normal acini; (b) myoepithelial
layer of a normal duct (some
apical staining in luminal layer);
(c) positive invasive breast tu-
mor cells; (d) endothelial cells
of a negative invasive breast tu-
mor. (B.II, a) positive staining in
capillaries, negative in fat cells;
(b) myoepithelial layer in nor-
mal glands (negative in inflam-
matory cells (⇑) and tumor cells
(↑)); (c) pericytes (negative in en-
dothelial cells in the bloodves-
sel (); (d) positive staining in
fibroblasts.
3.4, p < 0.01 in stroma; Fig. 5A and Supporting Information
Table 4). These discrepancies may be explained by different
roles of the protein in different cell types, such as inflam-
matory cells in stroma. To verify expression of caldesmon
in different cell types, we immunohistochemically stained
caldesmon in representative breast tissues (Fig. 5B). In nor-
mal ducts, caldesmon, a marker for smooth muscle differ-
entiation, is expressed in the outer, myoepithelial, layer of
cells, whereas no expression was observed in luminal cells
(Fig. 5B.I). In stroma, positive staining for caldesmon was
found in endothelial cells, but also in fibroblasts, reflect-
ing a myofibroblast phenotype commonly observed in ma-
lignant stroma. Therefore, in tumor epithelium, of which
the majority of samples were ER positive and of the lumi-
nal subtype, caldesmon expression is decreased, while trans-
formation of stroma into a reactive environment likely re-
sults in a higher number of myofibroblasts and endothelial
cells, and thus an overall elevated expression of caldesmon
(Fig. 5B.II).
3.5 Origin and differences between stromal clusters
The microdissected stroma samples were separated in the
PCA into two clusters, a homogeneous cluster consisting
mainly of stroma dissected from benign cryosections (ntotal =
10, nbenign = 6, nDCIS = 2, and nmalignant = 2), and a more het-
erogeneous cluster consisting of stromal samples dissected
mainly from malignant cryosections (ntotal = 8, nbenign = 2,
and nmalignant = 6). As was shown by the PCA (Fig. 3), the
largest origin for the difference between these two groups are
number and intensity of intracellular proteins, with more in-
tracellular proteins in the “reactive” stroma group. Although
proteins exclusively detected in one of the groups are likely
most informative, this was heavily biased against the “re-
active stroma” group, whereas no proteins were exclusively
detected in the “stroma” group. Therefore, for comparative
analysis between these two groups, only proteins that were
detected in both groups with a minimum of five observations
were included. Of the 522 selected proteins, 310 were differ-
entially abundant between the two groups, with a very strong
bias for proteins that were higher abundant in the “reactive
stroma” group (n = 227, p< 0.05). The larger number of cells
in the “reactive stroma” group strongly confounded results,
as was evident from the higher abundance ofmajor structural
and cellular machinery proteins, such as cytoskeletal, riboso-
mal, and histone proteins (Supporting Information Table 8).
In order to look beyond the proteins driving this bias, we
further investigated proteins that had a higher abundance in
the “stroma” group (n = 73, p < 0.05). Of these proteins,
immunoglobulin subunits were higher in abundance, along
with various stromal modeling proteins as collagens, proteo-
glycans, and endopeptidase inhibitors. We selected proteins
that had GO biological process terms ECM organization and
dissasembly, and constructed a string interaction protein net-
work in order to highlight differences in protein abundance
between the “stroma” and “reactive stroma” groups (Fig. 6).
Next to the previously identified proteins that had a lower
abundance in reactive stroma, such as the proteoglycans
decorin and lumican, glycoproteins versican, heparin sulfate
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Figure 6. STRING protein interaction
map of ECM organizing proteins de-
tected in microdissected stroma. Se-
lected proteins had a GO biologi-
cal process annotation that included
ECM organization and degradation.
Node size corresponds to absolute fold
change between stroma and reactive
stroma, ranging from log fold change
0 to 5.5. Node color corresponds to
change in abundance, with blue lower
in reactive stroma and red higher. Color
intensity corresponds to the signifi-
cance (–log p-value). Downregulated
proteins were given a negative sign.
2, and fibronectin had a higher abundance in the ‘reactive
stroma’ group, as well as chaperone proteins including heat
shock proteinsHPS90 alpha and beta (Fig. 6). These changes,
therefore, illustrate the formation of a different stromal envi-
ronment accompanying malignant tumor growth.
4 Discussion
We have microdissected 38 breast tissues with varying stages
of malignancy. Despite submicrogram amounts of starting
material, nearly 3000 proteins were identified in all com-
bined microdissected regions of interest. An advantage of
microdissection is that a single region of interest can be
isolated, which facilitates comparative analysis, but also re-
duces complexity and therefore increases proteome coverage
[24]. Corresponding with this, most protein identifications
were made in cells of epithelial origin, which could be dis-
sected relatively cleanly. The stromal compartment, however,
was largely heterogeneously intermingled with a wide vari-
ety of cell types in varying amounts between samples. Our
stromal samples could be separated into two groups, largely
based on the amount of intracellular proteins. Most stromal
samples from histologically malignant sections clustered in
a heterogeneous group that captured most of the variance of
the dataset. In contrast, stroma dissected from histologically
normal tissues clustered together in a homogeneous group.
Many of the additional proteins observed in the stroma of
malignant sections were intracellular proteins, likely due to a
transformation towards a more reactive stroma in malignant
sections, characterized by an increased number of immune
cells, fibroblasts and endothelial cells. This reactive stroma, or
desmoplasia, has earlier been recognized and characterized,
and is variable in amount and composition between tumors,
independent of degree of malignancy [25].
Overall, proteomic changes between normal, benign, and
malignant epithelium and stroma were readily observed, and
accurately reflected common alterations in the development
and progression of cancer [26]. Large numbers of proteins had
a lower abundance in malignant epithelium, including cell
adhesion and cytoskeletal organizing proteins, reflecting the
pro-migratory phenotype of tumor cells. Furthermore, sev-
eral mitochondrial proteins had a higher abundance, demon-
strating increased energy metabolism. Within the stromal
regions, changes mainly reflected desmoplasia, or reactiv-
ity of the stroma, as ECM proteins and cytoskeletal organiz-
ing proteins were enriched in malignant stroma as opposed
to epithelium. These findings are in line with a previous
study also demonstrating transition towards a more reactive
stroma in malignant tissues [27], while gene expression stud-
ies have shown that the composition of this stroma is predic-
tive for clinical outcome as well as therapy resistance [28–30].
Among the differentially abundant proteins were several
proteoglycans with a reduced expression inmalignant stroma
or epithelium, including mimecan and decorin. Proteogly-
cans have interesting roles in the development of cancer,
as a reduced expression in stroma is associated with recur-
rence both in ductal carcinoma in situ and invasive carcinoma
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[30,31]. In contrast, higher expression of decorin is associated
with chemotherapy resistance, a result of lower diffusion rates
of drugs in a more dense fibrillar space [28, 32].
Disconcordant changes in expression between tissue and
stroma were readily observed, such as for caldesmon, a cell
differentiation marker. A loss of expression of caldesmon is
associated with enhanced cellular motility due to cytoskele-
tal rearrangements; however, caldesmon appears to have a
dual role in tumor progression, as epithelial-to-mesenchymal
transformation results in higher expression of caldesmon in
vitro [33, 34]. Furthermore, an elevated level of caldesmon
was associated with tamoxifen therapy resistance in recur-
rent ER-positive breast cancer [35]. Given that changes in
expression of these and other proteins are often context de-
pendent, microdissection clearly shows its advantage as it
provides information constrained to a cell type or region of
interest.
In conclusion, we showed that major phenotypical and
corresponding proteomic changes were accurately captured
by microdissection of different cellular regions from fresh
frozen tissue sections with varying stages of disease. Pro-
tein recovery was high and unbiased, as the collected mate-
rial was readily lysed and digested as is, resulting in high
recovery of, for example, difficult and less soluble ECM and
membrane proteins. Microdissection therefore provides a
well-suited platform for characterization of proteome changes
between different clinical phenotypes. Moreover, while pro-
teomics analysis of the bulk tumor provides a good overview,
separate analysis of microdissected epithelial cells and the
tumor microenvironment gives a more detailed insight into
malignant transformation.
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